The treatment induced higher numbers of CTLA-4negative anti-CD123 CAR T cells which exhibited superior cytotoxicity compared to CTLA-4positive anti-CD123 CAR T cells against AML target cells in vitro and in vivo. This evidence concerns the gene IL3RA and acute myeloid leukemia.